Product Description
Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin has antibacterial activities against high-level gentamicin-resistant Enterococci, multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii et al. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835429/)
Mechanisms of Action: 30S Ribosomal Subunit Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous, Oral, Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Japan | Korea
Approved Indications: None
Known Adverse Events: None
Company: Meiji Seika Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Muscular Dystrophy, Duchenne
Phase 1: Healthy Volunteers|Pneumonia, Bacterial
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01659515 |
S-11-0001 | N/A |
No longer available |
Communicable Diseases |
None |
2019-07-21 |
Treatments |
|
NCT02459158 |
ME1100-CL-103 | P1 |
Completed |
Pneumonia, Bacterial |
2017-03-22 |
2019-03-20 |
Treatments |
|
NCT01907776 |
ME1100-CL-101 | P1 |
Completed |
Healthy Volunteers |
2013-12-01 |
2019-03-19 |
Treatments |
|
NCT01961830 |
ME1100-CL-102 | P1 |
Completed |
Healthy Volunteers |
2013-12-01 |
2019-03-20 |
Treatments |
|
NCT01918384 |
NORTH POLE DMD | P2 |
Unknown status |
Muscular Dystrophy, Duchenne |
2015-10-01 |
2019-03-19 |
Treatments |